Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia-Reference-Cited by-同舟云学术

Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia

Published:2018-08-24 Issue:1 Volume:44 Page:62-68
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Imatoh Takuya¹^ORCID,Sai Kimie¹,Takeyama Mayu¹²,Hori Katsuhito³,Karayama Masato⁴,Furuhashi Kazuki⁵,Segawa Katsunori¹,Kimura Michio⁶,Kawakami Junichi³,Saito Yoshiro¹

Affiliation:

1. Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan

2. Graduate School of Pharmaceutical Sciences; Tohoku University; Sendai Japan

3. Department of Hospital Pharmacy; School of Medicine; Hamamatsu University; Hamamatsu Japan

4. Department of Clinical Oncology; School of Medicine; Hamamatsu University; Hamamatsu Japan

5. Department of Internal Medicine; School of Medicine; Hamamatsu University; Hamamatsu Japan

6. Department of Medical Informatics; School of Medicine; Hamamatsu University; Hamamatsu Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12753/fullpdf

Reference20 articles.

1. Management of bone metastases in cancer: a review;Selvaggi;Crit Rev Oncol Hematol,2005

2. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer;Weinfurt;Ann Oncol,2005

3. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure;Body;J Bone Miner Res,2010

4. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, Double-Blind Study;Stopeck;J Clin Oncol,2010

5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D<sub>3</sub>;Biological and Pharmaceutical Bulletin;2023-01-01

2. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D ₃ )/Calcium Supplement;The Journal of Clinical Pharmacology;2022-05-02

3. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation;Biological and Pharmaceutical Bulletin;2021-12-01

4. Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation;YAKUGAKU ZASSHI;2021-08-01

5. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis;Scientific Reports;2021-01-13